PMID- 30781847
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2305-6320 (Print)
IS  - 2305-6320 (Electronic)
IS  - 2305-6320 (Linking)
VI  - 6
IP  - 1
DP  - 2019 Feb 13
TI  - Differential Methylation and Acetylation as the Epigenetic Basis of Resveratrol's 
      Anticancer Activity.
LID - 10.3390/medicines6010024 [doi]
LID - 24
AB  - Numerous studies support the potent anticancer activity of resveratrol and its 
      regulation of key oncogenic signaling pathways. Additionally, the activation of 
      sirtuin 1, a deacetylase, by resveratrol has been known for many years, making 
      resveratrol perhaps one of the earliest nutraceuticals with associated epigenetic 
      activity. Such epigenetic regulation by resveratrol, and the mechanism thereof, 
      has attracted much attention in the past decade. Focusing on methylation and 
      acetylation, the two classical epigenetic regulations, we showcase the potential 
      of resveratrol as an effective anticancer agent by virtue of its ability to 
      induce differential epigenetic changes. We discuss the de-repression of tumor 
      suppressors such as BRCA-1, nuclear factor erythroid 2-related factor 2 (NRF2) 
      and Ras Associated Domain family-1alpha (RASSF-1alpha) by methylation, PAX1 by 
      acetylation and the phosphatase and tensin homologue (PTEN) by both methylation 
      and acetylation, in addition to the epigenetic regulation of oncogenic NF-kappaB and 
      STAT3 signaling by resveratrol. Further, we evaluate the literature supporting 
      the potentiation of HDAC inhibitors and the inhibition of DNMTs by resveratrol in 
      different human cancers. This discussion underlines a robust epigenetic activity 
      of resveratrol that warrants further evaluation, particularly in clinical 
      settings.
FAU - Farhan, Mohd
AU  - Farhan M
AUID- ORCID: 0000-0002-1519-9644
AD  - College of Basic Sciences, King Faisal University, Hofuf 400-Al Ahsa-31982, Saudi 
      Arabia. mfarhan@kfu.edu.sa.
FAU - Ullah, Mohammad Fahad
AU  - Ullah MF
AD  - Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, 
      University of Tabuk, P.O. Box 741, Tabuk 71491, Saudi Arabia. m.ullah@ut.edu.sa.
FAU - Faisal, Mohd
AU  - Faisal M
AD  - Department of Psychiatry, University Hospital Limerick, Limerick V94 T9PX, 
      Ireland. mohd.faisal@hse.ie.
FAU - Farooqi, Ammad Ahmad
AU  - Farooqi AA
AD  - Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 44000, 
      Pakistan. ammadfarooqi@rlmclahore.com.
FAU - Sabitaliyevich, Uteuliyev Yerzhan
AU  - Sabitaliyevich UY
AD  - Department of Postgraduate Education and Research, Kazakhstan Medical University 
      KSPH, Almaty 050004, Kazakhstan. e.uteuliyev@ksph.kz.
FAU - Biersack, Bernhard
AU  - Biersack B
AD  - Organic Chemistry Laboratory, Department of Chemistry, University of Bayreuth, 
      Universitaetsstrasse 30, 95447 Bayreuth, Germany. bernhard.biersack@yahoo.com.
FAU - Ahmad, Aamir
AU  - Ahmad A
AUID- ORCID: 0000-0003-1784-5723
AD  - Department of Oncologic Sciences, Mitchell Cancer Institute, University of South 
      Alabama, Mobile, AL 36604, USA. aahmad@health.southalabama.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190213
PL  - Switzerland
TA  - Medicines (Basel)
JT  - Medicines (Basel, Switzerland)
JID - 101671069
PMC - PMC6473688
OTO - NOTNLM
OT  - acetylation
OT  - epigenetic
OT  - methylation
OT  - resveratrol
COIS- The authors declare no conflict of interest.
EDAT- 2019/02/20 06:00
MHDA- 2019/02/20 06:01
PMCR- 2019/02/13
CRDT- 2019/02/21 06:00
PHST- 2019/01/11 00:00 [received]
PHST- 2019/02/10 00:00 [revised]
PHST- 2019/02/11 00:00 [accepted]
PHST- 2019/02/21 06:00 [entrez]
PHST- 2019/02/20 06:00 [pubmed]
PHST- 2019/02/20 06:01 [medline]
PHST- 2019/02/13 00:00 [pmc-release]
AID - medicines6010024 [pii]
AID - medicines-06-00024 [pii]
AID - 10.3390/medicines6010024 [doi]
PST - epublish
SO  - Medicines (Basel). 2019 Feb 13;6(1):24. doi: 10.3390/medicines6010024.